Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
GAITHERSBURG, Md., July 22 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has received an SBIR (small business innovation research) grant from National Cancer Institute (NCI), National Institute of Health (NIH), for its novel siRNA
therapeutics to treat...
Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
Issuance Will Give Company Patents in Each of the Three Critical Areas of RNAi Therapeutic Development
PALO ALTO, Calif., March 17 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced that the United States Pate...
Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL )
announced today the global release of MISSION(R) In VIVO QUALITY and iScale
Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA
expected to allow researchers to successfully take the next step in ...
Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
GAITHERSBURG, Md., Oct. 28 /PRNewswire/ -- Sirnaomics, Inc.
(http://www.sirnaomics.com ) announced today that the company has received an SBIR
(small business innovation research) grant from National Cancer Institute
(NCI), National Institute of Health (NIH). Sirnaomics, Inc., a
M. D. Anderson Automates Laboratory Workflow with Stone Bond Technologies : EE-LIMS™ from Stone Bond Technologies Will Document Activities within the Laboratory Workflow at the siRNA Facility, Increasing Throughput, While Reducing Risks
The newly established Small Interfering Ribonucleic Acid (siRNA) Facility at M. D. Anderson Cancer Center has been charged with providing high-quality siRNA
screening services for both internal and external customers.
HOUSTON (Business Wire EON) July 1, 2008 -- M. D. ...
FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry
Quark Pharmaceuticals to develop drug candidate for prevention and treatment of delayed graft function in kidney transplantation
LONDON, June 25 /PRNewswire/ -- Silence Therapeutics plc (London AIM:
SLN) today announces that the U.S. Food and Drug Administration (FDA) has
approved a Qua...
Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
LONDON, March 13 /PRNewswire-FirstCall/ -- Silence Therapeutics plc
(AIM: SLN) today announces a collaboration with AstraZeneca (LSE: AZN),
focused on the development of a range of novel approaches for the delivery
molecules. The deal builds on Silence Therapeutics' leading
Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
ROCKVILLE, Md., Dec. 26 /PRNewswire/ -- Sirnaomics, Inc. announced
today that the company has received funding from a variety of Government
Programs. Sirnaomics, Inc. (http://www.sirnaomics.com ), a biopharmaceutical
company founded in early 2007, dedicates to advancing RNA interference
Aktiv-Dry Awarded Research Grant to Explore Inhalable siRNA Dry Powder Targeting RSV
BOULDER, Colo., Nov. 12 /PRNewswire/ -- Aktiv-Dry LLC has been awarded
an SBIR research grant from the Center for Disease Control and Prevention
(CDC) to explore the formulation of certain siRNA
products as inhalable dry
powders that might eventually be used to treat pulmonary disorders such a...
Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
ST. LOUIS, Oct. 18 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq:
SIAL) announced today the global release of the N-TER(TM) Nanoparticle
siRNA Transfection System. N-TER allows researchers to reproducibly
interrogate gene function, via siRNA
transfection, in model cell types that
PCI Biotech-led Consortium Awarded EUR1.1 m Eurostars Grant for siRNA
OSLO, March 23 /PRNewswire/ -- PCI Biotech Holding ASA, the Norwegian
drug delivery company, and siRNAsense AS, the Norwegian drug development
company, today announced that a PCI Biotech-led consortium focused on
cancer drug delivery has been ranked 3rd out of more than 300
Paper in Cell Cycle Reports Alfacell's ONCONASE(R) Targets siRNA
SOMERSET, N.J., Oct. 9 /PRNewswire-FirstCall/ -- Alfacell Corporation
(Nasdaq: ACEL ) today announced that a paper published in Cell Cycle (2008;
Vol. 7, Issue 20) reports that ONCONASE (ranpirnase) targets small
interfering RNA (siRNA), likely within the RNA-induced silencing complex
Mechanism for the in-vivo transport of siRNA
It all started with flowers: in the nineties of the last century Norwegian researchers discovered that additional copies of a particular gene in petunias inhibited its activity instead of reinforcing it as had been assumed. A few years later it was found that the mechanism is based on the degrada...
Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit
Although the Silencer
siRNA Labeling Kits were developed for labeling siRNA, they can
be readily adapted for labeling long dsRNA. The following protocol
can be used for t...
Your Data: Use of pSilencer 1.0-U6 siRNA Expression Vector in the Analysis of Synaptotagmin Location and Function
Iezzi M, Kouri G, Fukuda M, Wollheim CB
(2004) Synaptotagmin V and IX isoforms control
Ca 2+ -dependent insulin exocytosis. J Cell
In a recently published paper in the
Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect
Mike Byrom, Vince
Pallotta, David Brown*, and Lance Ford* Ambion, Inc.
2130 Woodward Street Austin, TX 78744-1832 * Corresponding authors email@example.com ,
po.src = 'https://apis.google.com/js/plusone.js';
var s = document.getElementsByTagName('script'); s.parentNode.insertBefore(po, s);